AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of the ~~general~~ formula (I),



~~General Formula~~ (I)

its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts and solvates,

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} ~~may be~~ are the same or different and are each independently ~~represent~~ selected from the group consisting of hydrogen, halogen, perhaloalkyl, substituted or unsubstituted ~~groups such as~~ linear or branched (C_1-C_3)alkyl, (C_3-C_7,)cycloalkyl, (C_1-C_3)alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, ~~heterocyclyl,~~ acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, hydroxyalkyl. alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, and sulfonic acids ~~and its derivatives~~,

R_{13} and R_{14} ~~may be~~ are the same or different and are each independently ~~represents~~ selected from the group consisting of hydrogen, substituted or unsubstituted ~~groups such as~~ linear or branched (C_1-C_3)alkyl, and (C_3-C_7)cycloalkyl, ~~optionally~~ or R_{13}, and R_{14} ~~along~~ taken together with the nitrogen atom to which they are attached, ~~may~~ form a 6 or 7- membered

heterocyclic ring, wherein the ring ~~may be further~~ is unsubstituted or substituted, and ~~it may have either~~ optionally contains one, two or three double bonds or ~~"additional heteroatoms", as defined above.~~ heteroatoms; and

~~"n"~~ n is an integer ranging from 1 to 2. ~~It is preferred that n be 1.~~

2. (Original) A compound according to Claim-1, which is selected from the group consisting of:

11-(2-N,N-Dimethylaminoethyl)isoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one hydrocloride salt;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one maleic acid salt;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one D,L-malic acid salt;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one oxalate salt;
11-[(2-N,N-Dimethylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one citrate salt;
11-[(2-N-cyclopropyl-N-methylamino)ethyl]-2-fluoroisoindolo[2,1-a]indol-6-one;
11-[2-N-cyclopropylaminoethyl]-2-flouroisonoindolo[2,1-a]indol-6-one;
2-Bromo-11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
2-Chloro-11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
4-Chloro-11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2-methylisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2-methoxyisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-4-methoxyisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-4-trifluoromethylisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-4-ethylisoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2,4-difluoroisoindolo[2,1-a]indol-6-one;
2,4-Dichloro-11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
3,4-Dichloro-11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
1,2,4-Trichloro11-[(2-N,N-dimethylamino)ethyl]isoindolo[2,1-a]indol-6-one;
11-[(2-N,N-Dimethylamino)ethyl]-2,4-dimethylisoindolo[2,1-a]indol-6-one;

11-[(2-N,N-Dimethylamino)ethyl]-3,4-dimethylisoindolo[2,1-a]indol-6-one;

1-Chloro-11-[(2-N,N-dimethylamino)ethyl]-4-methylisoindolo[2,1-a]indol-6-one;

3-Chloro-11-[(2-N,N-dimethyl-N-acetylamino)ethyl]-4-methylisoindolo[2,1-a]indol-6-one;

11-[(2-N,N-Dimethylamino)propyl]-4-methylisoindolo[2,1-a]indol-6-one;

3-Chloro-11-[(2-N-methylamino)ethyl]-4-methylisoindolo[2,1-a]indol-6-one;

3-Chloro-11-[(2-N-methyl-N-acetylamino)ethyl]-4-methylisoindolo[2,1-a]indol-6-one;

3-Chloro-11-[(2-N-methylamino)ethyl]-2-methoxyisoindolo[2,1-a]indol-6-one;

3-Chloro-11-[(2-N-methylamino)ethyl]-2-sulfoamidoisoindolo[2,1-a]indol-6-one;

3-Iodo-11-[(2-N-methylamino)ethyl]-2-methoxyisoindolo[2,1-a]indol-6-one;

2-Bromo-11-[(2-morpholin-1-yl)ethyl]isoindolo[2,1-a]indol-6-one;

2-Bromo-11-[2-(4-methylpiperazin-1-yl)ethyl]isoindolo[2,1-a]indol-6-one;

and its stereoisomers, its N-oxides, its polymorphs, its pharmaceutically acceptable salts and solvates.

3. (Currently amended) A pharmaceutical composition comprising ~~either of~~ a pharmaceutically acceptable carrier, ~~diluent/s, excipient/s or solvates along with~~ diluent or excipient and a therapeutically effective amount of a compound according to ~~Claim 1~~ claim 1, its tautomeric forms, its stereoisomers, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, or solvates.

4. (Currently amended) A pharmaceutical composition according to ~~Claim 3~~ claim 3, which is in the form of a tablet, capsule, powder, lozenge, suppository, ~~lozenges, suppositories,~~ syrup, solution, suspension or injectable, wherein said pharmaceutical composition is administered ~~in,~~ as a single dose or in multiple dose units.

5. (Original) Use of compound of general formula (I), as defined in Claim-1 or a pharmaceutical composition as defined in Claim-3 for preparing medicaments.

6. (Original) Use of compound of general formula (I), as defined in Claim-1 or a pharmaceutical composition as defined in Claim-9 for the treatment where a modulation of 5-HT activity is desired.

7. (Original) Use of a compound as claimed in Claim-1 for the manufacture of a medicament for the treatment and/or prevention of clinical conditions for which a selective action on 5-HT receptors is indicated.

8. (Original) Use of a compound as claimed in Claim-1 for the treatment and/or prevention of clinical conditions such as anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia. psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, sleep disorders and also disorders associated with spinal trauma and/or head injury.

9. (Original) Use of a compound as claimed in Claim-1 for the treatment of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea.

10. (Original) Use of a compound as claimed in Claim-l for the treatment of certain GI (Gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome) or chemotherapy induced emesis.

11. (Original) Use of a compound as claimed in Claim-l to reduce morbidity and mortality associated with the excess weight.

12. (Original) Use of a radiolabelled compound as claimed in Claim-1, as a diagnostic tool for modulating 5-HT receptor function.

13. (Original) Use of a compound as claimed in Claim 1 in combination with a 5-HT re-uptake inhibitor, and/or a pharmaceutically acceptable salt thereof.

14. (Original) A compound of the general formula (I), its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts and its pharmaceutically acceptable solvates for preparing a medicament.

15. (Original) A method for the treatment and/or prophylaxis of clinical conditions such as anxiety, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, sleep disorders and also disorders associated with spinal trauma and/or head injury which comprises administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in Claim-1.

16. (Original) A method for the treatment and/or prophylaxis of mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea which comprises administering to a patient in need thereof, an effective amount of a compound of general formula (I) as claimed in Claim-1.

17. (Original) A method for the treatment of certain GI (Gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome) or chemotherapy induced emesis using a compound of general formula (I) as claimed in Claim-1.

18. (Original) A method to reduce morbidity and mortality associated with the excess weight using a compound of general formula (I) as claimed in Claim-1.

19. (Currently amended) A process for the preparation of a compound according to claim 1 ~~of general formula (I), as defined in Claim 1, which comprises of any one of the following routes~~ comprising a step selected from one of steps i)-iv),

~~Route~~ i): cyclizing a compound of formula (II) using a Pd(0) or Pd(II) derivative as a catalyst ~~given below,~~



(II)

wherein X is halogen ~~such chloro, bromo or iodo, R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12}, R_{13}, R_{14} and "n", wherein all the symbols are as defined above~~,

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are the same or different and are each independently selected from the group consisting of hydrogen, halogen, perhaloalkyl, substituted or unsubstituted linear or branched (C_1-C_3)alkyl, (C_3-C_7,)cycloalkyl, (C_1-C_3)alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, hydroxyalkyl. alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, and sulfonic acids;

R_{13} and R_{14} are the same or different and are each independently selected from the group consisting of hydrogen, substituted or unsubstituted linear or branched (C_1-C_3)alkyl, and (C_3-C_7)cycloalkyl, or R_{13}, and R_{14} taken together with the nitrogen atom to which they are

attached, form a 6 or 7- membered heterocyclic ring, wherein the ring is unsubstituted or substituted, and optionally contains one, two or three double bonds or heteroatoms; and

n is an integer ranging from 1 to 2~~using a Pd(0) or Pd(II) derivative as a catalyst~~;

~~Route~~ ii): reacting a compound of formula (III) ~~given below,~~



(III)

~~wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} and "n" are as defined above~~, with ~~a suitable~~ an alkylating agent ~~such as~~ selected from the group consisting of R_{13} X, ~~or~~ R_{14} X, and ~~or~~ $R_{13}R_{14}X$ either in successive steps or in one step, wherein X is ~~good~~ a leaving group, ~~such as halogen and hydroxyl;~~

R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} re the same or different and are each independently selected from the group consisting of hydrogen, halogen, perhaloalkyl, substituted or unsubstituted linear or branched (C_1-C_3)alkyl, (C_3-C_7,)cycloalkyl, (C_1-C_3)alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, hydroxyalkyl. alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, and sulfonic acids; and

n is an integer ranging from 1 to 2;

~~Route~~ iii): reacting a compound of formula (IV) ~~given below,~~



(IV)

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, and R_8 are ~~as defined above~~ the same or different and are each independently selected from the group consisting of hydrogen, halogen, perhaloalkyl, substituted or unsubstituted linear or branched (C_1-C_3)alkyl, (C_3-C_7,)cycloalkyl, (C_1-C_3)alkoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, hydroxyalkyl. alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, and sulfonic acids;

with formaldehyde and a compound of formula (V) ~~given below,~~

$NR_{13}R_{14}$

(V)

wherein R_{13} and R_{14} are ~~as defined above~~ the same or different and are each independently selected from the group consisting of hydrogen, substituted or unsubstituted linear or branched (C_1-C_3)alkyl, and (C_3-C_7)cycloalkyl, or R_{13}, and R_{14} taken together with the nitrogen atom to which

they are attached, form a 6 or 7- membered heterocyclic ring, wherein the ring is unsubstituted or substituted, and optionally contains one, two or three double bonds or heteroatoms; or

~~Route~~ iv): either chemically or catalytically reducing ~~compounds~~ a compound of formula (I) containing a -C(=O) group~~/s~~ in the side chain, to the corresponding -C(OH,H) or -C(H,H) containing compound.

20. (Currently amended) A process according to ~~Claim 19~~ claim 19 further comprising ~~of carrying out~~ one or more of the following ~~optional~~ steps: i) removing ~~any~~ a protecting group; ii) resolving ~~the~~ a racemic mixture into pure enantiomers; ~~by the known methods~~ and iii) preparing a pharmaceutically acceptable salt ~~of a compound of formula (I) and/or iv preparing a pharmaceutically acceptable~~ or prodrug of the compound of formula (I) ~~thereof~~.

21. (Original) Novel intermediates defined of general formula (IV)



(IV)

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, and R_8 are as may be same or different and each independently represent hydrogen, halogen, perhaloalkyl, substituted or unsubstituted groups such as linear or branched $(C_1\text{-}C_3)$alkyl, $(C_3\text{-}C_7)$cycloalkyl, $(C_1\text{-}C_3)$alkoxy, cyclo$(C_3\text{-}C_7)$alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, sulfonic acids and its derivatives.

22. (Original) A process provided for the preparation of novel intermediate of the general formula (IV) which comprises of cyclizing compounds of formula (VIII)



(VIII)

wherein, R_1, R_2, R_3, R_4, R_5, R_6, R_7, and R_8 are as defined above; X is halogeno such as chloro, bromo or iodo, using a Pd(0) or Pd (II) derivative as a catalyst.